Ilan Hadar - 20 Feb 2026 Form 4 Insider Report for Silexion Therapeutics Corp (SLXN)

Role
Chairman and CEO, Director
Signature
/s/ Mirit Horenshtein Hadar, Attorney-in-fact
Issuer symbol
SLXN
Transactions as of
20 Feb 2026
Net transactions value
$0
Form type
4
Filing time
23 Feb 2026, 16:14:59 UTC
Previous filing
15 Aug 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hadar Ilan Chairman and CEO, Director C/O SILEXION THERAPEUTICS CORP, 12 ABBA HILLEL ROAD, RAMAT GAN, ISRAEL /s/ Mirit Horenshtein Hadar, Attorney-in-fact 23 Feb 2026 0001727727

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLXN Ordinary Shares Award $0 +64,350 +5740% $0.000000 65,471 20 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLXN Stock Option (right to buy Ordinary Shares) 956 20 Feb 2026 Ordinary Shares 956 $907.71 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflects adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively.
F2 The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
F3 There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
F4 The number of options to purchase ordinary share and underlying ordinary shares, and the exercise price of the options, reported in this row have been adjusted to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.